Drug-resistant typhoid fever is increasingly challenging global public health as strains of Salmonella enterica serovar Typhi develop resistance to multiple antibiotics and spread internationally. A genetic study published in The Lancet in 2022 found that antimicrobial resistance in typhoid has evolved repeatedly and independently, particularly in South Asia, with resistant strains spreading to other regions.
Genetic Mapping Reveals Widespread International Spread
Researchers analyzed the genetic sequences of 3,489 Salmonella Typhi strains collected in India, Pakistan, Bangladesh, and Nepal between 2014 and 2019. The team compared these findings against a global dataset of 4,169 genetic sequences gathered between 1905 and 2018 to track how resistance emerged, evolved, and moved geographically.
The analysis documented 138 international movements and 59 intercontinental transmissions of drug-resistant strains. In several instances, these introductions triggered sustained local transmission in the destination countries. According to the study’s findings, human migration, travel, and global mobility are primary drivers behind the spread of resistant strains to regions where they previously did not circulate.
Evolution Beyond Older Drugs to Fluoroquinolones
Historically, typhoid treatment relied on older first-line antimicrobials such as ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole. Over time, resistance expanded to newer classes of medications, notably fluoroquinolones. Furthermore, extensively drug-resistant typhoid strains emerged in Pakistan in 2016, rapidly expanding to become the dominant strain in that country.
Mutations conferring resistance to fluoroquinolones appeared independently dozens of times across South Asia, demonstrating the pathogen’s capacity to adapt under therapeutic pressure. This repeated, independent evolution highlights how single-mutation tracking is insufficient to capture the breadth of antimicrobial resistance development in the bacterium.
Emerging Challenges with Azithromycin Therapy
As older treatments and fluoroquinolones lost effectiveness, azithromycin emerged as a vital oral option for treating uncomplicated typhoid fever in endemic regions. However, clinical utility is facing fresh hurdles.
Genetic sequencing detected mutations in the acrB gene associated with azithromycin resistance. Researchers noted that these specific mutations first appeared in Bangladesh around 2013, with carrier strains increasing in prevalence over subsequent years. This ongoing shift underscores the shrinking pool of reliable, fully effective oral antibiotics for typhoid management.
Key Takeaways on Drug-Resistant Typhoid
- Global Spread: International travel and migration have driven intercontinental transmissions of resistant typhoid strains.
- Beyond First-Line Drugs: Resistance has progressed from older therapies to include fluoroquinolones and extensively drug-resistant profiles.
- Azithromycin Pressures: Mutations in the acrB gene linked to azithromycin resistance have been documented in Bangladesh since 2013, threatening a critical remaining treatment option.
Keep reading